SSSusanne Gjørup Sækmose

Susanne Gjørup Sækmose

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susanne Gjørup Sækmose has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The sole use of stem cells in treating fracture nonunion: a scoping review

    by Mads Riishede Hansen, Ming Ding, Steffen Søndergaard Folkvardsen, Susanne Gjørup Sækmose, Søren Kold, Bjarke Viberg, Chris Halling Dreyer

    Objective of this study This scoping-review aims to highlight the current modalities of sole use of stem cells in treating fracture nonunion updating a previous systematic review from 2013. We report solitary stem cell stimulation in literature in vivo studies to obtain current knowledge in understanding the crucial role of stem cells in enhancing fracture nonunion healing. Materials and methods This scoping review was conducted by systematical search in PubMed, Medline and clinicaltrials.gov with a timeframe from October 2012 to September 2024. Two authors independently screened all articles, and when included, the following information was extracted: type of nonunion, localization, type of stem cells, administered dose of stem cells, surgical information, type of scaffold, control group, evaluation method, time of evaluation post intervention, and adverse events. Results Of 4710 articles screened, 27 articles met the criteria for inclusion. In the reviewed articles, 2 out of 5 human studies, and 8 out of 12 animal studies with a control group reported a statistically significant effect of stem cells on bone healing when used in the treatment of fracture nonunion. Comparison of the studies was difficult due to heterogeneity. The administration of mesenchymal stem cells regarding adverse events was investigated in eight human studies. Conclusion Based on our reporting, the articles suggest that the perspectives of the sole use of mesenchymal stem cells in the management of fracture nonunion might be promising but remain inconclusive. Future research should be inspired by existing literature and focus on the development of well-standardized methodologies and results published.


  • Open Access

    Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark

    by Kamille Fogh, Alexandra R. R. Eriksen, Rasmus B. Hasselbalch, Emilie Sofie Kristensen, Henning Bundgaard, Susanne D. Nielsen, Charlotte S. Jørgensen, Bibi F. S. S. Scharff, Christian Erikstrup, Susanne G. Sækmose, et al.

    Background: COVID-19 is thought to be more prevalent among ethnic minorities and individuals with low socioeconomic status. We aimed to investigate the prevalence of SARS-CoV-2 antibodies during the COVID-19 pandemic among citizens 15 years or older in Denmark living in social housing (SH) areas. Methods: We conducted a study between January 8th and January 31st, 2021 with recruitment in 13 selected SH areas. Participants were offered a point-of-care rapid SARS-CoV-2 IgM and IgG antibody test and a questionnaire concerning risk factors associated with COVID-19. As a proxy for the general Danish population we accessed data on seroprevalence from Danish blood donors (total Ig ELISA assay) in same time period. Results: Of the 13,279 included participants, 2296 (17.3%) were seropositive (mean age 46.6 (SD 16.4) years, 54.2% female), which was 3 times higher than in the general Danish population (mean age 41.7 (SD 14.1) years, 48.5% female) in the same period (5.8%, risk ratios (RR) 2.96, 95% CI 2.78–3.16, p > 0.001). Seropositivity was higher among males (RR 1.1, 95% CI 1.05–1.22%, p = 0.001) and increased with age, with an OR seropositivity of 1.03 for each 10-year increase in age (95% CI 1.00–1.06, p = 0.031). Close contact with COVID-19-infected individuals was associated with a higher risk of infection, especially among household members (OR 5.0, 95% CI 4.1–6.2 p < 0,001). Living at least four people in a household significantly increased the OR of seropositivity (OR 1.3, 95% CI 1.0–1.6, p = 0.02) as did living in a multi-generational household (OR 1.3 per generation, 95% CI 1.1–1.6, p = 0.003). Only 1.6% of participants reported not following any of the national COVID-19 recommendations. Conclusions: Danish citizens living in SH areas of low socioeconomic status had a three times higher SARS-CoV-2 seroprevalence compared to the general Danish population. The seroprevalence was significantly higher in males and increased slightly with age. Living in multiple generations households or in households of more than four persons was a strong risk factor for being seropositive. Results of this study can be used for future consideration of the need for preventive measures in the populations living in SH areas.


  • Open Access

    Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors

    by Christian Erikstrup, Christoffer Egeberg Hother, Ole Birger Vestager Pedersen, Kåre Mølbak, Robert Leo Skov, Dorte Kinggaard Holm, Susanne Sækmose, Anna Christine Nilsson, Patrick Terrence Brooks, Jens Kjaergaard Boldsen, et al.

    Background: The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and also to calculate the infection fatality rate (IFR). These measures may help the authorities to make informed decisions and adjust the current societal interventions. Blood donors comprise approximately 4.7% of the similarly aged population of Denmark and blood is donated in all areas of the country. The objective of this study was to perform real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population based IFR. Methods: All Danish blood donors aged 17-69 years giving blood April 6 to 17 were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between areas and an estimate of the IFR was calculated. The seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CI). Results: The first 9,496 blood donors were tested and a combined adjusted seroprevalence of 1.7% (CI: 0.9-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers a combined IFR in patients younger than 70 is estimated at 82 per 100,000 (CI: 59-154) infections. Conclusions: The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR, including only individuals with no comorbidity, is likely several fold lower than the current estimate. This may have implications for risk mitigation. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.